Clinical trials referenced in this document:
Documents that mention this clinical trial
Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial
Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial
Funding for this research was provided by:
Received: 11 June 2021
Accepted: 16 September 2021
First Online: 2 October 2021
: The ASPECT-NP study was conducted in accordance with the principles of Good Clinical Practice and was approved by the appropriate institutional review boards and regulatory agencies. All participants or legally acceptable representatives provided informed consent.
: Not applicable.
: AFS reports advisory board membership for Combioxin SA. CJB, ZZ, EJ, WG, H-PF, JAH, BY, EGR, SB, and CDA are employees of MSD and may own stock and/or hold stock options in Merck & Co., Inc., Kenilworth, NJ, USA. MHK reports advisory board and speaker’s bureau fees and institutional research funding from MSD.